- Home
- ECX vs CAPR Comparison
ECX vs CAPR Comparison
Compare ECX & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECX
- CAPR
- Stock Information
- Founded
- ECX 2017
- CAPR 2005
- Country
- ECX China
- CAPR United States
- Employees
- ECX N/A
- CAPR N/A
- Industry
- ECX EDP Services
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ECX Technology
- CAPR Health Care
- Exchange
- ECX Nasdaq
- CAPR Nasdaq
- Market Cap
- ECX 589.5M
- CAPR 600.7M
- IPO Year
- ECX N/A
- CAPR N/A
- Fundamental
- Price
- ECX $2.19
- CAPR $10.25
- Analyst Decision
- ECX Strong Buy
- CAPR Strong Buy
- Analyst Count
- ECX 1
- CAPR 8
- Target Price
- ECX $3.20
- CAPR $33.75
- AVG Volume (30 Days)
- ECX 2.7M
- CAPR 3.2M
- Earning Date
- ECX 08-07-2025
- CAPR 08-06-2025
- Dividend Yield
- ECX N/A
- CAPR N/A
- EPS Growth
- ECX N/A
- CAPR N/A
- EPS
- ECX N/A
- CAPR N/A
- Revenue
- ECX $805,604,079.00
- CAPR $17,363,588.00
- Revenue This Year
- ECX $26.72
- CAPR $258.96
- Revenue Next Year
- ECX $30.34
- CAPR $8.02
- P/E Ratio
- ECX N/A
- CAPR N/A
- Revenue Growth
- ECX 19.98
- CAPR N/A
- 52 Week Low
- ECX $0.76
- CAPR $3.52
- 52 Week High
- ECX $3.25
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- ECX 73.84
- CAPR 47.85
- Support Level
- ECX $1.62
- CAPR $9.45
- Resistance Level
- ECX $1.96
- CAPR $11.58
- Average True Range (ATR)
- ECX 0.15
- CAPR 1.44
- MACD
- ECX 0.05
- CAPR -0.14
- Stochastic Oscillator
- ECX 86.86
- CAPR 54.08
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.